FDA approves 2nd generation subcutaneous ICD

Candace Stuart | | Cardiovascular Business | Heart Rhythm

The FDA approved Boston Scientific’s Emblem subcutaneous implantable defibrillator (S-ICD) system, which is expected to be available in the U.S. by the third quarter of this year.

This is the second generation of the device, which became the first FDA-approved S-ICD in 2012. The technology uses a pulse generator and an electrode to provide a less invasive treatment for patients at risk of sudden cardiac arrest. Physicians implant the device under the patient’s skin, and it does not require lead implantation in the heart.

The newer generation is 19 percent thinner with a 40 percent longer projected life than its predecessor, according to Boston Scientific. It can be paired with the Latitude NXT patient management system for patient monitoring.

The Emblem S-ICD also received CE mark, with an expected European launch in May.

Candace Stuart, Contributor

Related Content

LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Eko Health’s AI platform for digital stethoscopes granted new CPT code
Predicting sudden cardiac death after a heart attack may be impossible—for now
Concomitant ablation surgery during heart operations boosts long-term survival
Johnson & Johnson MedTech gains FDA approval for Varipulse PFA system
Boston Scientific agrees to acquire AFib ablation company

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."